Hutchmed Crystalline Forms Patent Grant US12600713B2

USPTO granted patent US12600713B2 to Hutchmed Limited for novel crystalline forms of the compound 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide. The patent protects specific solid-state forms, solvates, and crystalline forms of this pharmaceutical compound, along with associated pharmaceutical compositions and methods of preparation and use.\n\nFor pharmaceutical manufacturers and researchers, this grant establishes exclusive rights for Hutchmed over these specific crystalline forms. Competitors developing generic versions would need to either design around these claims or challenge their validity. This is a standard patent grant event that creates enforceable intellectual property rights but does not impose compliance obligations on other parties.